|
|
HIV Update 2002 (5) - MayPublished by: Datamonitor Published: May. 29, 2002 - 28 Pages Table of ContentsEXECUTIVE SUMMARY Key Market Events in May 2002 STRUCTURE OF UPDATE ANALYSIS OF KEY DEVELOPMENTS IN MAY 2002 COMPANY HEADLINES OraSure Technologies Receives Conditional FDA Approval New Partnership to Produce Broad Spectrum Diagnostic System Tampering of GSK Drug Labels RESEARCH AND DEVELOPMENT HEADLINES Resistance Testing Recommended for Patients Switching from Agenerase Benefits of Triple HIV Therapy Confirmed Merck Vaccine Under Clinical Trial HIV Vaccine Vaunted as Best Means of Controlling AIDS Second Phase III Trial Promising for T-20 Resistance Selected For by Repeated STIs AIDSVAX Passes Seventh Safety Review DISEASE SPECIFIC HEADLINES Hope for Natural HIV Defense as CD8+ Cells Inhibit HIV Growth Scientists Identify Novel Viral Reservoir HIV Patients Over 50 Benefit from Better Compliance UK Looks at Routine HIV Tests for TB Patients Californian Doctors Have to Report New HIV Cases US Clinical Trials Less Likely to Involve Ethnic Minorities Transplant a Potential Option for HCV/HIV Co-Infected Patients Preferential Infection of HIV-specific CD4 T Cells - Limiting the Impact of STIs? Manganese Halts HIV Replication EMERGING MARKETS HEADLINES Youth HIV Infection Rate Stabilizing in South Africa APPENDIX Datamonitor's Infectious Disease Business Unit Research Background Contacts and Further Reading AbstractA complete assessment of the events that impacted the global HIV market in May 2002 - A complete assessment of the R&D, corporate, disease specific and emerging market events that impacted the HIV market in May 2002. The updates are generated from ongoing clinical and commercial research, intensive opinion leader interviews, published and statistical sources and Datamonitor's own in-house HIV expertizeGet Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||